US Patent

US10166184 — Method of lyophilizing liposomes

Method of Use · Assigned to Celator Pharmaceuticals Inc · Expires 2032-10-15 · 6y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of lyophilizing liposomes that contain two or more encapsulated drugs.

USPTO Abstract

Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Drugs covered by this patent

Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3149`	—	Cytarabine

Patent Metadata

Patent number: US10166184
Jurisdiction: US
Classification: Method of Use
Expires: 2032-10-15
Drug substance claim: No
Drug product claim: Yes
Assignee: Celator Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.